A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

NCT07669779 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

348

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: AK146D1 for injection
DRUG: AK112 Injection
DRUG: Platinum chemotherapy
DRUG: Osimertinib

Sponsor

Akeso